Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer


15th World Congress on Cancer Therapy, Biomarkers & Clinical Research

Philadelphia, USA

Adewale Victor Aderemi

Osun State University, Nigeria

Title: Effects of palladium-based compounds on human neuroblastoma cell lines with acquired resistance to platinum drugs


Biography: Adewale Victor Aderemi


Despite significant advances, neuroblastoma remains one of the most difficult childhood cancers to cure, with less than 40% of patients with high-risk disease being long-term survivors. Resistance acquisition to chemotherapy is a major cause of treatment failure in high-risk cases. Here, we tested the effects of novel palladium-based (SW005c, SW009b, SW012a, SW017a and SW018a) compounds on the viability of the human neuroblastoma cell line UKF-NB-3 and its sub-lines adapted to the clinically approved platinum drugs cisplatin (UKF-NB-3rCDDP1000), carboplatin (UKF-NB-3rCARBO2000), and oxaliplatin (UKF-NB-3rOXALI2000) by MTT assay. The palladium compounds SW005c, SW009b, SW012a, SW017a, and SW018a interfered with the viability of the cells in low micromolar concentrations (1.4µM – 4µM). Although some degree of heterogeneity in the response of the cell lines to the palladium compounds was observed, in particular with regard to SW017a and SW018a, there was no pattern indicating that acquired platinum drug-resistance would be associated with decreased sensitivity to the investigated palladium compounds. This suggests that the anti-cancer mechanism of action of the palladium compounds differs from that of the approved platinum drugs. In conclusion, the newly synthesised palladium-based compounds should be further studied in additional cell line models and animal experiments.